Emerging Cellular Therapies at the Forefront of Cancer Immunotherapy

处于癌症免疫治疗前沿的新兴细胞疗法

• 批准号: 10540496
• 负责人: TERRY L. SHEPPARD
• 金额: $ 1.1万
• 依托单位: KEYSTONE SYMPOSIA
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-01-29 至 2023-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10540496
• 关键词: Achyrocline; Address; Affect; Alberta province; Antibodies; Area; Benign; Biodistribution; Biological Products; Biology; Canada; Cell Culture Techniques; Cell Therapy; Cells; Cellular biology; Cellular immunotherapy; Chemistry; Collaborations; Development; Drug Kinetics; Educational workshop; Effectiveness; Engraftment; Event; Extravasation; Functional disorder; Future; Gene Transfer; Genetic; Genome engineering; Hematologic Neoplasms; Immune; Immunosuppression; Individual; Industrialization; Intuition; Knowledge; Learning; Malignant - descriptor; Malignant Neoplasms; Metabolic; Methodology; Modeling; Normal tissue morphology; Outcome; Research; Research Personnel; Scientist; Solid Neoplasm; Speed; Technology; Therapeutic; Therapeutic Index; Time; Tissues; Toxic effect; Translations; Tumor Biology; Work; cancer cell; cancer immunotherapy; cancer therapy; career; clinical implementation; clinical practice; differential expression; fitness; holistic approach; improved; in vivo; insight; interest; multidisciplinary; neoplastic; new technology; next generation; novel; novel strategies; posters; programs; resilience; small molecule; success; symposium; synthetic biology; trafficking; translational scientist

ABSTRACT Support is requested for a Keystone Symposia conference entitled Emerging Cellular Therapies at the Forefront of Cancer Immunotherapy, organized by Drs. Francesco Marincola, Lisa Butterfield, David Stroncek and Marcela Maus. The conference will be held in Banff, Alberta, Canada from January 29-February 2, 2023. Cellular immunotherapy for the treatment of hematological malignancies and solid tumors is rapidly progressing. Progress depends upon the development of better products that match the challenges limiting effectiveness such as survival and engraftment, trafficking to cancer tissues, engagement with cancer cells, and resilience to immune-suppressive factors while at the same time de-risking toxicity. This can be only achieved following a holistic approach to achieve an optimal therapeutic index. Such estimation goes beyond the selection of antigenic targets based of differential expression between benign and neoplastic tissues as is intuitively done for small molecules, antibodies and other biologics where the engagement of the product with its target is dependent on stable chemistry and predicable pharmacokinetics. Cell therapies instead are affected by active rather than passive biodistribution, and context dependent potency. Thus, a broader range of factors need to be considered like product-dependent variability (fitness, unpredictable pharmacokinetics due non-specific trapping, sequestration and extravasation into normal tissues, and variable rates of in vivo expansion). Individual cancer immune biology may affect differential trafficking to benign compared to malignant tissues under different conditions of chemo-attraction, hampered engagement with cancer cells due to physical or functional barriers, immune suppression, and cellular dysfunction due to unfavorable metabolic conditions. This conference gathers expertise from all areas, to propose an integrated path forward to successful implementation of novel cellular therapeutics, particularly for solid tumors.

摘要 请求支持在2010年12月15日至16日在纽约举行的题为“新兴细胞疗法”的Keystone专题讨论会。 癌症免疫疗法前沿，由Francesco Marincola、丽莎巴特菲尔德、大卫斯特龙切克博士组织 还有马塞拉·莫斯会议将于2023年1月29日至2月2日在加拿大阿尔伯塔省班夫市举行。 用于治疗恶性血液病和实体瘤的细胞免疫疗法正在迅速发展。 进步进步取决于开发更好的产品，以满足限制 有效性，如存活和植入，运输到癌组织，与癌细胞的接合， 和对免疫抑制因素的适应力，同时降低毒性风险。这只能是 采用整体方法实现最佳治疗指数。这种估计超出了 基于良性和肿瘤组织之间的差异表达的抗原靶标的选择， 直观地为小分子，抗体和其他生物制剂，其中产品与 其靶点依赖于稳定的化学性质和可预测的药代动力学。细胞疗法是 受主动而非被动生物分布的影响，以及环境依赖性效力。因此， 需要考虑多种因素，如产品依赖性变异性（适应性、不可预测的药代动力学 由于非特异性捕获、隔离和溢出到正常组织中，以及体内的变化率 扩展）。个体癌症免疫生物学可能会影响与良性肿瘤相比的差异性运输。 恶性组织在不同条件下的化学吸引力，阻碍了与癌细胞的接触， 身体或功能障碍，免疫抑制和细胞功能障碍，由于不利的代谢 条件本次会议汇集了所有领域的专业知识，提出了一条综合的前进道路， 成功实施新的细胞疗法，特别是用于实体瘤。